Potassium binders

Potassium binders

Drug monograph · NCLEX study reference
Trade names	Kayexalate, Veltassa
Therapeutic class	Potassium-lowering agent
Pharmacologic class	Cation exchange resin (sodium polystyrene sulfonate); potassium binder (patiromer)
Onset / peak / duration	Hours (not for emergency hyperkalemia); patiromer onset about 7 hours.
Half-life / level	Acts in the gut; monitor potassium.
Routes	PO (oral), Rectal
High-alert (ISMP)	No
Black box warning	None
Antidote / reversal	Supportive care.
Pregnancy / lactation	Use if needed.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Potassium binders (brand names Kayexalate, Veltassa) — Potassium-lowering agent; Cation exchange resin (sodium polystyrene sulfonate); potassium binder (patiromer).

Identification

• Therapeutic class: Potassium-lowering agent.
• Pharmacologic class: Cation exchange resin (sodium polystyrene sulfonate); potassium binder (patiromer).

Pharmacology

• Mechanism of action: Exchange or bind potassium in the gut for elimination in stool.
• Onset / peak / duration: Hours (not for emergency hyperkalemia); patiromer onset about 7 hours.
• Half-life / therapeutic level: Acts in the gut; monitor potassium.

Clinical use

• Indications: Hyperkalemia (nonemergency).
• Usual dose, route, frequency: PO or rectal (sodium polystyrene sulfonate); patiromer PO once daily.
• Maximum dose / adjustments: Not for life-threatening hyperkalemia (too slow); separate from other oral drugs.

Safety

• Contraindications: Bowel obstruction or hypomotility (intestinal necrosis risk with sodium polystyrene sulfonate), hypokalemia.
• Black box warning: None.
• Interactions: Bind many oral drugs (separate sodium polystyrene sulfonate and other oral drugs by hours; patiromer by at least 3 hours); sodium polystyrene sulfonate with sorbitol increases necrosis risk.
• Pregnancy / lactation: Use if needed.
• High-alert: No.

Adverse effects

• Common side effects: Constipation, nausea, GI discomfort; patiromer causes low magnesium.
• Serious effects to report: Intestinal necrosis (sodium polystyrene sulfonate), severe constipation, hypokalemia, hypomagnesemia (patiromer).
• Antidote / reversal: Supportive care.

Nursing process

• Assessment before administration: Potassium, bowel function and motility.
• Interventions during therapy: Confirm bowel motility; separate from other oral medications; reassess potassium.
• Monitor: Potassium, magnesium (patiromer), bowel function.
• Evaluation / expected outcome: Lowered serum potassium.

Patient teaching

• Patient teaching: Take other medicines separated in time; report severe constipation or abdominal pain.
• Notify provider if: Severe abdominal pain or distension, no bowel movement, muscle weakness.
• Administration tips: Separate from other oral drugs; not for emergencies.